Impaired sensitivity in non-responders to pegylated interferon plus ribavirin therapy assessed by 2′-5′-oligoadenylate synthetase activity

被引：0
|
作者：
Shindo, Michiko
Hamada, Kazushige
Morikawa, Teruhisa
Harano, Yuichi
Nakajima, Tomoaki
Okuno, Tadao
机构：
[1] Akashi Municipal Hosp, Akashi, Hyogo, Japan
[2] Kyoto Inst Technol, Kyoto 606, Japan
来源：
HEPATOLOGY | 2007年 / 46卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
333
引用
收藏
页码：388A / 388A
页数：1
相关论文
共 50 条
  • [1] In vivo interferon system assessed by 2′-5′ oligoadenylate synthetase activity in chronic hepatitis C virus patients treated with pegylated interferon and ribavirin
    Shindo, Michiko
    Hamada, Kazushige
    Morikawa, Teruhisa
    Harano, Yuichi
    Nakajima, Tomoaki
    Okuno, Tadao
    HEPATOLOGY RESEARCH, 2008, 38 (12) : 1213 - 1220
  • [2] Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: A meta-analysis
    Camma, Calogero
    Cabibbo, Giuseppe
    Bronte, Fabrizio
    Enea, Marco
    Licata, Anna
    Attanasio, Massimo
    Andriulli, Angelo
    Craxi, Antonio
    JOURNAL OF HEPATOLOGY, 2009, 51 (04) : 675 - 681
  • [3] Triple therapy (interferon, ribavirin, amantadine) for non-responders of combination therapy with interferon and ribavirin?.
    Thuluvath, PJ
    Maygers, J
    HEPATOLOGY, 2000, 32 (04) : 557A - 557A
  • [4] Analysis of relapse rates in pegylated interferon and ribavirin non-responders treated with daily consensus interferon and ribavirin
    Hassanein, Tarek
    Ghalib, Reem H.
    Zein, Nizar N.
    Rothstein, Kenneth D.
    Joshi, Shobha N.
    Kwo, Paul Yien
    Hammond, Janet
    HEPATOLOGY, 2007, 46 (04) : 824A - 824A
  • [5] Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
    Fernando L Gonçales
    Camila A Moma
    Aline G Vigani
    Adriana FCF Angerami
    Eduardo SL Gonçales
    Raquel Tozzo
    Maria HP Pavan
    Neiva SL Gonçales
    BMC Infectious Diseases, 10
  • [6] Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
    Goncales, Fernando L., Jr.
    Moma, Camila A.
    Vigani, Aline G.
    Angerami, Adriana F. C. F.
    Goncales, Eduardo S. L.
    Tozzo, Raquel
    Pavan, Maria H. P.
    Goncales, Neiva S. L.
    BMC INFECTIOUS DISEASES, 2010, 10
  • [7] Interferon plus ribavirin in chronic hepatitis C non-responders to recombinant α-interferon
    Bresci, G
    Parisi, G
    Bertoni, M
    Scatena, F
    Capria, A
    JOURNAL OF VIRAL HEPATITIS, 2000, 7 (01) : 75 - 78
  • [8] Intravenous silibinin as 'rescue treatment' for on-treatment non-responders to pegylated interferon/ribavirin combination therapy
    Rutter, Karoline
    Scherzer, Thomas-Matthias
    Beinhardt, Sandra
    Kerschner, Heidrun
    Staettermayer, Albert F.
    Hofer, Harald
    Popow-Kraupp, Theresia
    Steindl-Munda, Petra
    Ferenci, Peter
    ANTIVIRAL THERAPY, 2011, 16 (08) : 1327 - 1333
  • [9] Interferon-alpha plus ribavirin combination therapy for the treatment of chronic hepatitis C in interferon non-responders
    Hasan, F
    Asker, H
    Al Shamali, M
    Al Kalaoui, M
    Al Nakib, B
    HEPATO-GASTROENTEROLOGY, 2000, 47 (36) : 1642 - 1644
  • [10] Amantadine, interferon and ribavirin (triple therapy) for non-responders of combination therapy with interferon and ribavirin - A pilot study.
    Thuluvath, PJ
    Maygers, J
    Conlan, JL
    HEPATOLOGY, 2001, 34 (04) : 586A - 586A
12345